

April 02, 2025

BSE Limited

Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd.,

Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') - Investment in Neoethicals Chile SpA

Pursuant to Regulation 30 of the SEBI Listing Regulations, we would like to inform that the Board of Directors of Caplin Point Far East Limited, Hong Kong, a material Subsidiary of the Company, had approved the investment in Neoethicals Chile SpA through the purchase of all its shares, at the meeting of its Board held on 1st April, 2025.

The details required under regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as Annexure A.

Kindly take the same on record.

Thanking You,

Sincerely Yours

For Caplin Point Laboratories Limited

Venkatram G

General Counsel & Company Secretary
Membership No. A23989

Encl: A/a

Annexure – A

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc	Name of the Target entity: Neoethicals Chile SpA. The current share capital of the Company comprises of 3,000 equity shares of One Thousand Chilean Peso each. The turnover of the Company during Jan to Dec 2024 is 278,565,412 Chilean Pesos (equivalent US \$295,222).
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length	The target entity will be a related party of the Company and other subsidiaries after the acquisition. Except the above, the Promoter/ promoter group/ group companies does not have any interest in the transaction.
3.	Industry to which the entity being acquired belongs	Marketing and Distribution of Pharmaceutical products.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The target entity shall be the front end entity for Caplin Point Laboratories Limited in the Chilean market for direct sales, marketing and distribution of the products manufactured by Caplin Point Laboratories Limited.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No specific prior approvals are required for the acquisition.
6.	Indicative time period for completion of the acquisition	Acquisition of the target company has been completed on 1 st April, 2025.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	The entire consideration has been paid through banking channels by Caplin Point Far East Limited, which is the wholly owned subsidiary of the Company.
8.	Cost of acquisition and/or the price at which the shares are acquired	3000 shares are acquired at the face value of One Thousand Chilean Peso per share (equivalent to USD 3000).
9.	Percentage of shareholding / control acquired and / or number of shares acquired	The entire share capital of Neoethicals Chile SpA has been acquired by Caplin Point Far East Limited thereby making it a wholly owned Subsidiary of Caplin Point Far East Limited and a step down subsidiary of the Company.

10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Neoethicals Chile SpA operates in Chile in the Pharmaceutical Marketing and Distribution business. Neoethicals Chile SpA was incorporated by public deed on 31st March, 2015. It primarily serves the Chilean market. The turnover of Neoethicals Chile SpA for the last three years is as follows:</p> <p>CY 2024 – Chilean Peso 278,565,412 (US\$ 295,222) CY 2023 – Chilean Peso 49,995,906 (US\$ 59,585) CY 2022 – Chilean Peso Nil</p> <p>Neoethicals Chile SpA had distributed the products of Caplin Point Laboratories Limited in the Chilean market and hence the acquisition was made at face value to make Neoethicals Chile SpA a Subsidiary of the Company. This is a strategic investment reflecting our long-term confidence in our business model and growth potential.</p>
-----	---	---

For Caplin Point Laboratories Limited

Venkatram G
General Counsel & Company Secretary
Membership No. A23989